Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review

Hiroto Arino; Naokazu Muramae; Mitsumasa Okano; Kenta Mori; Kazunori Otsui; Kazuhiko Sakaguchi

doi:10.7759/cureus.24952

Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review

Cureus. 2022 May 12;14(5):e24952. doi: 10.7759/cureus.24952. eCollection 2022 May.

Authors

Hiroto Arino¹, Naokazu Muramae², Mitsumasa Okano³, Kenta Mori³, Kazunori Otsui³, Kazuhiko Sakaguchi³

Affiliations

¹ Department of General Internal Medicine, Kobe City Medical Center General Hospital, Kobe, JPN.
² Department of General Internal Medicine, Kobe University Graduate School of Medicine, Kobe, JPN.
³ Department of General Internal Medicine, Kobe University Hospital, Kobe, JPN.

Abstract

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare clinical entity characterized by "remitting," "seronegative," and "symmetrical" synovitis with pitting edema on the dorsum of the hands and feet. Although rheumatic or malignant diseases are diseases that are known to coexist with RS3PE, other factors such as medication, infection, and vaccination have been reported to be associated with RS3PE. Here, we present a case of RS3PE syndrome that satisfied all four diagnostic criteria of RS3PE (pitting edema in the limbs, acute onset, age ≥ 50 years, and/or rheumatoid factor negativity) after mRNA-1273 SARS-CoV-2 vaccination.

Keywords: mrna-1273 (moderna); parvovirus b19; peripheral edema; rs3pe; sars-cov-2 vaccination.

Publication types

Case Reports